Table 1. Patient and CT Characteristics.
| Characteristic | Patients, No. (%) (N = 199) |
|---|---|
| Age, median (range), y | 66 (20-93) |
| Sex | |
| Men | 133 (66.8) |
| Women | 66 (33.2) |
| Smoking status | |
| Never | 86 (43.2) |
| Current or former | 98 (49.2) |
| Unknown | 15 (7.5) |
| ECOG PS score | |
| 0–1 | 152 (76.4) |
| ≥2 | 47 (23.6) |
| CT characteristics | |
| Existing abnormal finding | 165 (82.9) |
| Details of abnormal finding | |
| Preexisting interstitial lung abnormalities | 37 (18.6) |
| Ground glass attenuation | 24 (12.1) |
| Reticulation | 20 (10.1) |
| Honeycombing | 5 (2.5) |
| Traction bronchiectasis | 0 |
| Emphysema | 46 (23.1) |
| Lung metastasis | 87 (43.7) |
| Radiation pneumonitis | 6 (3.0) |
| Consolidation | 8 (4.0) |
| Lymphangiosis carcinomatosa | 3 (1.5) |
| Treatment and tumor response | |
| ICI | |
| Nivolumab | 177 (88.9) |
| Pembrolizumab | 22 (11.1) |
| Line of ICI therapy | |
| 1 | 34 (17.1) |
| 2 | 68 (34.2) |
| 3 | 52 (26.1) |
| ≥4 | 45 (22.6) |
| ICI cycles, No. | |
| 1 | 14 (7.0) |
| 2 | 20 (10.1) |
| 3 | 15 (7.5) |
| 4 | 24 (12.1) |
| ≥5 | 126 (63.3) |
| Best tumor response | |
| CR | 2 (1.0) |
| PR | 30 (15.1) |
| SD | 55 (27.6) |
| PD | 84 (42.2) |
| Unknown | 28 (14.1) |
Abbreviations: CR, complete response; CT, computed tomography; ECOG PS, Eastern Cooperative Oncology Group performance status; ICI, immune checkpoint inhibitor; PD, progressive disease; PR, partial response; SD, stable disease.